According to Future Market Insights’ most recent industry analysis, the global Clot Busting Drugs Market Size is valued at around US$ 28.8 billion in 2022 and is expected to grow at a CAGR of close to 7.3% over the forecast period, reaching a valuation of US$ 58.4 billion in 2032.
The global market for Clot Busting therapies is quickly expanding as a result of fast molecular and biological customisation in clot-busting therapies, rising prevalence of cardiovascular illnesses worldwide, and an ageing population. The Clot Busting Drugs market is estimated to develop significantly in the forecast years due to the increased need for Clot Busting Drugs in the prevention of heart attacks and strokes.
Unlock growth potential with industry expertise. Download your market sample report now: https://www.futuremarketinsights.com/reports/sample/rep-gb-15689
Because Clot Busting Drugs are not reaching customers at the requested rate due to a lack of awareness and the drugs’ adverse effects, companies are developing novel Clot Busting Drugs with minimal side effects at accessible prices. This is predicted to increase the uptake and consumption of clot-busting medications dramatically. Rising product releases and approvals are likely to boost market growth throughout the forecast period.
Key Takeaways from Market Study:
- Anticoagulants are the leading product segment, accounting for approximately 36.7% of the market in 2021. Due to the rise in chronic diseases, anticoagulant medicine development has become more molecularly and biologically advanced, and emerging nations are increasingly using novel oral anticoagulants.
- Pulmonary Embolism is the largest indication, accounting for approximately 31.2% of the market in 2021, owing to an increasing number of cancer patients and those with a family history of cardiovascular difficulties.
- Because of the increased demand for instruments such as safety syringes, prefilled syringes, and auto-injectors to reduce needle stick injuries, the injectable category is the main segment in drug administration route, accounting for more than half of the global market share.
- As of 2021, Hospital Pharmacy is the dominant distribution channel, accounting for around one-third of the global market by value, owing to a wide range of product availability, convenience, and patients’ reliance on hospitals for treatments.
- North America leads the global Clot Busting Drugs market by region, accounting for 32.4% of revenue in 2021, and is predicted to maintain its position with an 8.0% CAGR during the forecasted years.
“Rising initiatives to promote health benefits of Clot Busting Drugs, as well as the increasing awareness about the prevention of heart attacks and strokes is set to propel the sales of Clot Busting Drugs devices across the globe,” says an analyst of Future Market Insights.
Clot Busting Drugs Market Report Available At a Discounted Price: https://www.futuremarketinsights.com/request-discount/rep-gb-15689
Market Competition:
The market for Clot Busting Drugs is quite competitive due to the presence of numerous local or regional players. The companies are concentrating on implementing different business strategies, such as product launches, drug development, and geographic expansions. For Instance:
- In Dec 2021, Janssen Pharmaceutical received U.S. FDA approval for its oral anticoagulant called XARELTO (rivaroxaban). The drug was approved for 2 indications for pediatric category which includes prophylaxis of DVT or deep vein thrombosis resulting in pulmonary embolism.
- AstraZeneca’s Brilinta (ticagrelor) received FDA approval for its P2Y12 receptor antagonist, an oral, reversible drug that prevents platelet activation, in June 2020 to lower the risk of a stroke or a first heart attack in patients with high-risk of coronary artery disease (CAD).
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the clot-busting drugs market in its latest study, presenting a historical demand assessment of 2016 to 2021 and projections for 2022 to 2032.
The research study is based on product– (thrombolytic drugs, anti-platelet drugs, anticoagulants and others), indication- (pulmonary embolism, deep vein thrombosis, atrial fibrillation and others), route of administration- (oral and injectable), distribution channel- (hospital pharmacy, drug store, online pharmacy and retail pharmacy) across seven regions of the world.
Request Tailored Insights to Outperform in the Clot Busting Drugs Market: https://www.futuremarketinsights.com/customization-available/rep-gb-15689
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs